One of the most common questions pilots ask Aviation Medical Examiners is deceptively simple: “Can I take this medication and still fly?”
Unfortunately, the answer has historically been anything but simple.
Many medications – including common over-the-counter (OTC) drugs – can be incompatible with flying because of sedation, slowed reaction time, impaired judgment, visual effects, dizziness, or other undesirable side effects. Just as importantly, the medical condition being treated may itself make flying unsafe, even when the medication is acceptable.
Under 14 CFR 61.53, pilots have an affirmative responsibility to refrain from exercising airman privileges when they know, or have reason to know, that a medical condition, medication, or treatment makes them unable to meet the applicable medical requirements [1].
Over-the-Counter Does Not Mean Safe for Pilots
A medication does not have to require a prescription to interfere with flight safety.
Sedating antihistamines are a classic example. Diphenhydramine, better known as Benadryl, may significantly impair alertness even when the person taking it does not feel particularly drowsy. The FAA’s current antihistamine guidance requires a 60-hour post-dose observation period after diphenhydramine before flying. Cetirizine (Zyrtec), often marketed as a less-sedating antihistamine, still carries a 48-hour no-fly period under FAA guidance [2].
The same concern can apply to sleep aids, muscle relaxants, narcotic pain medications, motion-sickness drugs, cough and cold preparations, and other seemingly routine treatments.
When you cannot verify the FAA’s specific policy for a medication, the safest choice is to self-ground until you can. For potentially impairing medications, the FAA has traditionally used a useful pharmacologic rule of thumb: wait at least five times the medication’s maximum elimination half-life after the last dose. If the half-life is unavailable, the FAA may use five times the maximum recommended dosing interval [3].
For example, a medication taken every four to six hours would result in a minimum 30-hour wait using the FAA’s five-times-the-maximum-dose-interval method. FAA guidance for sleep aids illustrates how widely these intervals can vary: zaleplon (Sonata) requires 12 hours after the last dose, many zolpidem formulations require at least 24 hours, and temazepam (Restoril) requires 72 hours [4].
Importantly, five half-lives does not make an otherwise prohibited medication acceptable. It is a safety framework for determining when the effects of certain intermittently used medications should have dissipated.
Half-life information can often be found in the medication’s FDA-approved prescribing information, usually under Clinical Pharmacology or Pharmacokinetics. The National Library of Medicine’s DailyMed database is an excellent source for current FDA drug labeling [5].
The Problem With the Old FAA Medication Lists
For years, pilots and AMEs relied heavily on the FAA’s Do Not Issue/Do Not Fly (DNI/DNF) guidance.
The list remains useful. “Do Not Issue” medications generally require an AME to defer the medical application for FAA review, while “Do Not Fly” medications require pilots to observe specified restrictions before returning to flight duties [6].
But the DNI/DNF guidance was never intended to be a comprehensive FAA medication database. The FAA itself cautions that its pharmaceutical guidance is not totally inclusive or comprehensive and that pilots should not infer FAA approval simply because a particular medication does not appear on a list [7].
A detailed reading of the FAA Guide for Aviation Medical Examiners provides substantially more information. Separate guidance exists for antihistamines, antidepressants, blood-pressure medications, diabetes drugs, cholesterol medications, migraine therapies, sleep aids, weight-loss medications, anticoagulants, and many other drug classes.
The problem is accessibility. Determining the FAA’s policy for a single drug may require navigating several sections of the AME Guide, understanding the underlying diagnosis, determining whether a CACI or Special Issuance applies, and interpreting terminology written primarily for physicians and Aviation Medical Examiners.
Third-Party FAA Medication Databases
Several organizations have attempted to fill that gap.
Pilots can search the Wingman Med FAA Medication Search, the AMAS Medication Database, or – if they are members – the AOPA FAA Medication Database.
These resources can provide excellent general guidance and are much easier to search than hundreds of pages of FAA policy. However, none should be considered a substitute for current FAA guidance or individualized aeromedical advice. FAA medication policy changes regularly, and the answer may depend not merely on the drug, but also on the dose, frequency, indication, side effects, medical certificate class, and stability of the underlying condition.
The FAA Has Just Announced an Even Better Resource
In October 2026, the FAA introduced an important new resource: the FAA MedGuide.
Version 1.0 of the MedGuide is now available through the FAA’s Guide for Aviation Medical Examiners. The first release intentionally includes only medications the FAA categorizes as “ALLOWED”, meaning they may be used during flight or other safety-related duties when the underlying condition is aeromedically acceptable and the pilot has no significant adverse effects [8].
That alone represents a significant improvement. Pilots taking commonly acceptable medications, such as many non-sedating allergy treatments or cholesterol medications, now have a much more direct way to verify current FAA policy rather than trying to prove acceptability by the medication’s absence from a prohibited list. Existing FAA guidance, for example, recognizes multiple non-sedating antihistamines and numerous cholesterol-lowering drugs as acceptable when applicable certification requirements are satisfied.
The FAA also states that, when starting a new medication, a 48-hour initial observation or “ground trial” is required in most cases, although individual medications may require shorter or longer periods [8].
The current MedGuide is only the beginning. The FAA says future releases will add conditional and unacceptable medications. That should eventually give pilots a single resource for determining whether a medication:
- Can be taken while continuing to fly;
- Requires an initial ground trial or post-dose waiting period;
- Is acceptable only under a CACI, Special Issuance, or other FAA monitoring pathway; or
- Is incompatible with aviation duties altogether.
What Should Pilots Do Today?
For now, pilots should consider the FAA MedGuide the best starting point—not the final word.
If your medication is clearly listed as allowed, confirm that you have satisfied any required observation period, that the underlying condition itself is compatible with flight, and that you are experiencing no adverse effects.
If the medication is not listed, do not assume that means it is prohibited. The current MedGuide is deliberately incomplete. Check the FAA AME Guide, a reputable aviation-medication database, or consult an experienced AME or aviation medicine expert.
As the MedGuide expands, this process should become substantially easier. Pilots will increasingly be able to access current FAA medication policy themselves and make an informed decision about whether to keep flying, temporarily self-ground, discuss an alternative treatment with their physician, or obtain expert aeromedical assistance before their certification is affected.
For medication-specific aeromedical guidance, pilots can also start with the Wingman Med FAA Medication Search.
References
[1] Federal Aviation Administration, “14 CFR § 61.53—Prohibition on Operations During Medical Deficiency,” Guide for Aviation Medical Examiners. [Online]. Available: FAA § 61.53 guidance. Accessed: Oct. 4, 2026.
[2] Federal Aviation Administration, “Allergy—Antihistamines & Immunotherapy Medication,” Guide for Aviation Medical Examiners. [Online]. Available: FAA AME Guide. Accessed: Oct. 4, 2026.
[3] Federal Aviation Administration, “Over-the-Counter Medications,” Guide for Aviation Medical Examiners. [Online]. Available: FAA OTC Medication Guidance. Accessed: Oct. 4, 2026.
[4] Federal Aviation Administration, “Sleep Aids,” Guide for Aviation Medical Examiners. [Online]. Available: FAA Sleep Aid Guidance. Accessed: Oct. 4, 2026.
[5] National Library of Medicine, “DailyMed—Official Provider of FDA Label Information.” [Online]. Available: DailyMed information. Accessed: Oct. 4, 2026.
[6] Federal Aviation Administration, “Do Not Issue—Do Not Fly,” Guide for Aviation Medical Examiners. [Online]. Available: FAA DNI/DNF Guidance. Accessed: Oct. 4, 2026.
[7] Federal Aviation Administration, “Pharmaceuticals (Therapeutic Medications),” Guide for Aviation Medical Examiners. [Online]. Available: FAA Pharmaceutical Guidance. Accessed: Oct. 4, 2026.
[8] Federal Aviation Administration, “MedGuide,” Guide for Aviation Medical Examiners, ver. 1.0, Oct. 1, 2026. [Online]. Available: FAA MedGuide. Accessed: Oct. 4, 2026.
[9] Wingman Med, “FAA Medication Search.” [Online]. Available: Wingman Med FAA Medication Search. Accessed: Oct. 4, 2026.
